The FINANCIAL — Bayer HealthCare on April 1 announced the primary outcomes of the Phase 3 SIGHT study at the 30th Asia-Pacific Academy of Ophthalmology Congress in Guangzhou, China.
In the study of neovascular wet age-related macular degeneration (wet AMD) in China, patients receiving aflibercept solution for intravitreal injection 2 milligrams (mg) achieved superiority in visual and anatomical endpoints compared to photodynamic therapy. The treatment was initiated with one injection per month for three consecutive doses, followed by one injection every two months. At 28 weeks, patients treated with aflibercept solution for injection gained almost three lines (14.0 letters) compared to a gain of 3.9 letters in the group receiving photodynamic therapy. Based on the 28-week results of the SIGHT study, as well as those of the previous VIEW 1 and VIEW 2 trials, Bayer HealthCare has submitted an application for marketing authorization of aflibercept solution for injection for the treatment of patients with wet AMD to the China Food and Drug Administration.
“The Phase 3 SIGHT data, along with results from the previous VIEW 1 and VIEW 2 studies, are encouraging news for patients with wet AMD and their physicians in China,” said Dr. Joerg Moeller, Member of the Bayer HealthCare Executive Committee and Head of Global Development. “With age being the most prominent risk factor for wet AMD and the Chinese population over 60 expected to reach 480 million by 2050, it is important to provide patients with more options that could not only improve their vision but also minimize the burden for patients and their families.”
Discussion about this post